Stallergenes Reports Results of Pediatric Study

A Phase III pediatric trial of French drugmaker Stallergenes’ Oralair Grasses confirmed the drug’s efficacy.

Data from the VO52.06 study, which was carried out on 280 patients suffering from allergic rhinoconjunctivitis, demonstrated a significant reduction in symptoms, Stallergens said.

Based on the results, the company will request the indication of Oralair Grasses be extended to children and hopes to launch the drug in Europe by the end of the year.

The company also has proposed two Phase III trials in the U.S. to begin in 2009.